S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Get ready for Christmas shopping-sprees with these 2 winners
Li Auto smashes estimates proving EVs can be profitable
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Get ready for Christmas shopping-sprees with these 2 winners
Li Auto smashes estimates proving EVs can be profitable
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Get ready for Christmas shopping-sprees with these 2 winners
Li Auto smashes estimates proving EVs can be profitable
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Teva Pharma is the way to play the re-rise of generic drugs
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Lemonade nears breakout, short interest surges, analysts bearish
ULTA stock is setting up to swing for the fences
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Get ready for Christmas shopping-sprees with these 2 winners
Li Auto smashes estimates proving EVs can be profitable

Roivant Sciences (ROIV) Earnings Date, Estimates & Call Transcripts

$9.09
-0.01 (-0.11%)
(As of 11/28/2023 ET)
Compare
Today's Range
$8.88
$9.15
50-Day Range
$8.38
$13.19
52-Week Range
$5.01
$13.24
Volume
7.08 million shs
Average Volume
4.50 million shs
Market Capitalization
$7.31 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.33
Skip Charts & View Estimated and Actual Earnings Data

ROIV Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

ROIV Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Roivant Sciences Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20232($0.30)($0.25)($0.28)
Q2 20232($0.30)($0.29)($0.30)
Q3 20232($0.32)($0.32)($0.32)
Q4 20232($0.36)($0.33)($0.35)
FY 20238($1.28)($1.19)($1.24)
Q1 20241($0.33)($0.33)($0.33)
Q2 20241($0.33)($0.33)($0.33)
Q3 20241($0.33)($0.33)($0.33)
Q4 20241($0.33)($0.33)($0.33)
FY 20244($1.32)($1.32)($1.32)

ROIV Earnings Date and Information

Roivant Sciences has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, February 12th, 2024 based off prior year's report dates.

Roivant Sciences Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
2/12/2024
Estimated)
------- 
8/14/2023Q2 2023($0.28)($0.38)($0.10)($0.38)$24.49 million$21.60 million    
6/28/2023Q4 2023($0.41)($0.20)+$0.21($0.35)$18.94 million$27.38 million
2/13/2023Q3 2023($0.36)($0.49)($0.13)($0.49)$14.29 million$17.05 million
11/14/2022Q2 2023($0.41)($0.42)($0.01)($0.42)$6.71 million$12.53 million
8/15/2022Q1 2023($0.30)($0.48)($0.18)($0.48)$6.45 million$4.32 million
6/28/2022Q4 2022($0.25)($0.39)($0.14)($0.39)$11.94 million$9.22 million
2/14/2022Q3 2022($0.23)($0.41)($0.18)($0.41)$10.13 million$24.34 million    
11/15/2021Q2 2022($1.06)($0.87)+$0.19($1.42)$5.30 million$13.99 million
9/21/2021Q1 2022-($0.37)($0.37)($0.37)-$7.74 million












Roivant Sciences Earnings - Frequently Asked Questions

When is Roivant Sciences's earnings date?

Roivant Sciences has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, February 12th, 2024 based off last year's report dates. Learn more on ROIV's earnings history.

How much revenue does Roivant Sciences generate each year?

Roivant Sciences (NASDAQ:ROIV) has a recorded annual revenue of $61.28 million.

How much profit does Roivant Sciences generate each year?

Roivant Sciences (NASDAQ:ROIV) has a recorded net income of -$1.01 billion. ROIV has generated -$1.32 earnings per share over the last four quarters.

What is Roivant Sciences's EPS forecast for next year?

Roivant Sciences's earnings are expected to grow from ($1.55) per share to ($1.39) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:ROIV) was last updated on 11/29/2023 by MarketBeat.com Staff

My Account -